D913BCZ
Brachytherapy Hypopharynx to None with Californium 252 (Cf-252), Low Dose Rate (LDR) Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | D Radiation Therapy |
| Body System | 9 Ear, Nose, Mouth and Throat |
| Operation | 1 Brachytherapy |
| Body Part | 3 Hypopharynx |
| Approach | B Low Dose Rate (LDR) |
| Device | C Californium 252 (Cf-252) |
| Qualifier | Z None |
Procedure Overview
Brachytherapy for ear, nose, mouth, and throat conditions involves placing a radioactive source directly into or next to a tumor, commonly in the oral cavity, tongue base, or nasopharynx. Because the source sits so close to the target tissue, it delivers a concentrated dose to the tumor while limiting exposure to surrounding healthy structures, which is valuable in a region crowded with nerves and tissue responsible for speech and swallowing.
The radioactive material may be temporary, removed after a set period, or permanently implanted depending on the isotope and clinical goal. This approach is often used alongside external beam radiation or surgery, particularly when a tumor recurs or when sparing normal tissue is a priority.
Anatomy & Axis Detail
Hypopharynx
The hypopharynx, the lowest portion of the pharynx connecting the oropharynx to the esophagus, is a site where brachytherapy may supplement external radiation to boost dose to residual or localized disease after initial treatment. Its narrow, tubular geometry and proximity to the larynx and esophagus make source placement technically demanding, often requiring intraluminal applicators positioned endoscopically. Swallowing and airway protection are major functional concerns in this region, so brachytherapy is generally reserved for carefully selected cases where a boost can improve local control without unacceptable damage to these functions. Because the hypopharynx is anatomically distinct from the more familiar oropharynx and larynx, accurate identification of this specific subsite is important both for treatment planning and for documenting exactly what structure received the implanted dose.
Modality Qualifier: Low Dose Rate (LDR)
Low Dose Rate (LDR) denotes brachytherapy using a source of lower activity that remains implanted or applied over an extended period, from many hours to a few days, exploiting continuous low-level irradiation for tumor control. This differs from High Dose Rate (HDR), which compresses the same general goal into brief, higher-intensity sessions, and LDR is often chosen for permanent seed implants such as certain prostate treatments.
Isotope: Californium 252 (Cf-252)
Californium-252 is a neutron-emitting source rather than a gamma or beta emitter, used in specialized brachytherapy for radioresistant tumors such as certain cervical or head and neck cancers where neutrons' higher relative biological effectiveness offers an advantage. It is far less commonly used than the gamma-emitting seed isotopes and is documented separately because its neutron output changes tissue interaction and shielding requirements.
Coding & Documentation
Coders need documentation identifying the specific isotope or source used and confirming that the radioactive material was placed within or immediately adjacent to the target structure, not delivered from an external machine. The procedure note should specify whether the source is temporary or permanent, since this affects the qualifier assigned.